inhibiting angiotensin II-increased cardiomyocyte hypertrophy 13 and enhancing myocardial angiogenesis, both in vivo and in vitro, by induction of vascular endothelial growth factor. 14 Silent information regulator 2 (Sir2) is a member of the sirtuin deacetylase family of enzymes that removes acetyl groups from lysine residues in histones and other proteins in a NAD-dependent manner. 15, 16 SIRT1 is a mammalian ortholog of the Sir2 protein. Caloric restriction extends the life span of animals and a recent study has identified Sir2 as mediating the effects of caloric restriction. 17 Overexpression of Sir2 extends the lifespan in model organisms. SIRT1 deacetylates a variety of proteins, inducing p53, and has cytoprotective effects. 18 It has been reported that resveratrol may modulate Sir2 activity. 19 Because resveratrol has both cardioprotective and immunomodulatory effects, it may favorably modulate the myocardial injury induced by myocarditis, which we investigated in a rat model of EAM.
Methods

Animals
Female Lewis rats (8 weeks old) were purchased from Charles River (Kanagawa, Japan). Animal care and experimental protocol were approved by the Institutional Animal Care and Use Committee of Kitasato University.
emulsified solution (0.25 ml) or adjuvant alone was subcutaneously injected into the footpads of rats. The day of myosin injection was defined as day 0.
Experimental Protocols
Resveratrol (Sigma, St Louis, MO, USA: lot number 065K5203) was dissolved in dimethylsulfoxide (DMSO) at concentration of 20 mg/ml, and 0.5 ml of resveratrol dissolved in DMSO or the same amount of DMSO alone was injected intraperitoneally into the rats once daily. The dose of resveratrol was equivalent to 50 mg/kg.
Protocol 1 Vehicle or resveratrol was administered to rats from 1 day prior to immunization to 14 days afterward. The rats were killed after echocardiographic examination 14 days after immunization. Body weight, heart weight, and tibial length were measured. The hearts were used for analysis of histology, gene expression, and protein expression.
Protocol 2 Vehicle or resveratrol was started 1 day before immunization and continued until echocardiographic examination 21 days later, after which the rats were killed and the same measurements taken.
Protocol 3 Vehicle or resveratrol was started 1 day after immunization, continued for 14 days and then the rats were killeded after echocardiographic examination. The weights and tibial length were measured as per the other 2 protocols.
Heart Rate (HR) and Blood Pressure (BP)
Systolic BP (SBP) and HR were recorded by the tail cuff method (Softron BP-98A, Tokyo, Japan). 21 For measuring SBP, rats were placed in a warm chamber maintained at 40°C for 10 min in an individual Plexiglas restrainer. Three pressure measurements were recorded for each rat, and the average SBP was calculated.
Echocardiography
Transthoracic echocardiographic analysis was performed using a ProSound SSD-4000 (ALOKA, Tokyo, Japan) with a 7.5-MHz imaging transducer. 2-2-2 tribromoethanol (Aldrich, 0.4-0.6 mg/kg) was used for anesthesia. M-mode echocardiography was performed at the papillary muscle level, and the left ventricular end-diastolic dimension, endsystolic dimension and left ventricular posterior wall thickness were measured; fractional shortening (FS) was calculated as described. 22 
Western Blotting
The hearts were removed and immediately frozen in liquid nitrogen. Lysates were obtained by homogenization of tissue in ice-cold buffer as described. 22 Cardiac tissue lysates were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, and the proteins were transferred onto polyvinylidene difluoride membranes as described. 22 For analysis of SIRT1, the blots were probed with the antiSir2 antibody (1:2,000 Upstate Biotechnology, Lake Placid, NY, USA) or anti-glyceraldehye-3-phosphate dehydrogene antibody (GAPDH; 1:5,000, Research Diagnosis, Flandeuns, NJ, USA).
Quantitative Reverse Transcription (RT)-Polymerase Chain Reaction (PCR)
RNA was prepared from heart tissue by the acid-guanidinium-phenol chloroform method. cDNA was synthesized using the SuperScript first-strand synthesis system (Invitrogen, Carlsbad, CA, USA) and then subjected to PCR with SYBR green (Applied Biosystems, Foster City, CA, USA) as the detected fluoroprobe. Incorporation of the SYBR green dye into the PCR products was monitored in a real-time manner with the ABI PRISM 7900HT Sequence Detection System, and the threshold cycle, which defines the PCR cycle at which exponential growth of PCR products begins, was calculated. The PCR reactions were cycled 35 times by a 3-step cycle procedure (denaturation 95°C, 15 s; annealing 60°C, 30 s; extension 72°C, 30 s). mRNA levels of B-type natriuretic peptide (BNP), tumor necrosis factor-(TNF-), inducible nitric oxide synthase (iNOS), manganese superoxide dismutase (Mn-SOD), copper/zinc superoxide dismutase (Cu/Zn-SOD), and SIRT1 were measured. Each of the RNA samples was normalized with an endogenous control (GAPDH mRNA). The primers used for the PCR analysis was designed using OLIGO Primer Analysis Software (TaKaRa, Kyoto, Japan) and oligonucleotides were synthesized at Invitrogen (Tokyo, Japan). The primer sequences were as follows:
BNP 
Histopathology
The rats were killed on day 14 and their hearts were fixed in 3.7% formaldehyde, embedded in paraffin and sectioned. The sections were stained by the hematoxylin -eosin or Mallory -Azan method and the microscopic findings were expressed as infiltration and fibrosis scores for the respective stains. Morphometric quantification was performed with Mac-Scope Image software (version 2.59; Mitani Corp, Fukui, Japan) on a Macintosh computer. 23 The outline of the area of cell infiltration or fibrosis was traced by hand, the profile area was assessed automatically and the area ratio (affected area/total area in percent) was calculated.
Immunohistochemical Analysis of SIRT1 Expression
Heart tissue was embedded in OCT compound, snapfrozen on dry ice, and stored at -70°C. Samples were sectioned on a cryostat at 10 m and then fixed for 5 min in acetone at 4°C. The sections were incubated with anti-SIRT1 antibody (rabbit IgG, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-actinin antibody (mouse IgG, Sigma) at 4°C overnight. Next, sections were incubated with fluorescent isothiocyanate-labeled anti-rabbit IgG and rhodaminelabeled anti-mouse IgG antibodies at room temperature for 30 min. Nuclei were stained using TOTO-3 (Invitorogen Carlsbad, CA, USA). Sections were analyzed by confocal microscopy (Carl Zeiss, Oberkochen, Germany).
Statistical Analysis
All values are expressed as mean ± SEM. Differences between groups were compared using Student's t-tests. A p-value <0.05 was considered as significant.
Results
HR and BP
At 14 days after immunization, we examined the effect of resveratrol on HR and BP. The SBP of vehicle-treated myosin-immunized rats was decreased compared with that of vehicle-treated unimmunized rats (96.4±5.1 mmHg vs 115.2±3.9 mmHg, p<0.05, Table 1 ). The BP of resveratroltreated myosin-immunized rats was not different from that of vehicle-treated unimmunized rats. Echocardiographic Analysis At 14 days after immunization, we examined the effect of resveratrol on cardiac function using echocardiography ( Table 2 , Fig 1) . The FS of vehicle-treated myosin-immunized rats was decreased compared with that of vehicletreated unimmunized rats (44.6±3.4% vs 68.5±3.0%, p< 0.05). Resveratrol treatment attenuated the decrease in FS in myosin-immunized rats, thus preserving the cardiac function of EAM rats.
Postmortem Analysis
At 14 days after immunization, the heart weight/tibial length ratio of myosin-immunized rats was increased by 1.81-fold compared with vehicle-treated unimmunized rats (31.9±2.6 mg/mm vs 17.6±0.2 mg/mm, p<0.05, Table 3 , Fig 2) . In contrast, the heart weight/tibial length ratio of resveratrol-treated myosin-immunized rats was increased by 1.29-fold compared with resveratrol-treated unimmunized rats (22.9±1.9 mg/mm vs 17.8±0.4 mg/mm, p<0.05). Thus, resveratrol significantly suppressed the increase in heart weight of EAM rats.
Histopathological Analysis
The area of cell infiltration in resveratrol-treated myosinimmunized rats was significantly decreased compared with vehicle-treated myosin-immunized rats (2.6±1.5% vs 26.4± 3.6%, p<0.05; Fig 3, Table 4 ). The area of fibrosis in resveratrol-treated myosin-immunized rats was decreased from that of vehicle-treated myosin-immunized rats (5.5±3.2% vs 28.0±4.6%, p<0.05; Fig 3, Table 4 ). Overall, resveratrol attenuated the inflammation and fibrosis of the myocardium of EAM rats.
BNP Gene Expression
BNP mRNA of myosin-immunized rats was increased by 12.4±2.2-fold compared with vehicle-treated unimmunized rats (Table 5) . BNP mRNA of resveratrol-treated myosin-immunized rats was increased by 1.6±0.5-fold compared with vehicle-treated unimmunized rats. Resveratrol significantly suppressed the increase in BNP mRNA in the myocardium of EAM rats. 
Expression of Inflammatory Markers
The levels of both TNF-and iNOS mRNA were analyzed using quantitative RT-PCR (Table 6 ). TNF-mRNA was increased by 46.2±14.4-fold, and resveratrol suppressed TNF-expression. iNOS mRNA was increased in EAM rats and resveratrol significantly decreased its expression.
Expression of Antioxidant Genes
The level of expression of the antioxidant enzymes, Mn-SOD and Cu/Zn-SOD, was analyzed using quantitative RT-PCR (Table 7) . Mn-SOD mRNA increased by 7.5±1.4-fold, and Cu/Zn-SOD mRNA by 3.0±1.1-fold in the myocardium of EAM rats. Resveratrol significantly attenuated the expression of both enzymes.
SIRT1 Expression
The level of SIRT 1 mRNA was analyzed using quantitative RT-PCR. SIRT1 mRNA was increased by 2.2±0.2-fold in vehicle-treated myosin-immunized rats compared with vehicle-treated unimmunized rats (Fig 4A) . The amount of SIRT1 protein was also increased in vehicle-treated myosin-immunized rats (Fig 4B) . The immunofluorescence study showed that the SIRT1 protein was mainly localized in infiltrating mononuclear cells (Fig 5) . 
Effect of Resveratrol at 3 Weeks After Immunization
Three weeks after immunization (ie, Protocol 2), the FS of resveratrol-treated rats was greater than that of vehicletreated rats (66.7±3.0% vs 34.4±4.4%, p<0.05, Table 8 ). The heart weight/tibial length ratio of the resveratroltreated rats was smaller compared with vehicle-treated rats (25.4±3.5 mg/mm vs 36.0±2.3 mg/mm, p<0.05, Table 9 ). Thus, resveratrol effectively prevented myocarditis at 3 weeks after the immunization.
Effect of Resveratrol on EAM After Immunization
When vehicle or resveratrol was started 1 day after immunization (ie, Protocol 3), the FS of resveratrol-treated rats was greater than that of the vehicle-treated rats (63.8±3.0% vs 36.3±4.3%, p<0.05, Table 10 ). The heart weight/tibial length ratio of resveratrol-treated rats was smaller compared with vehicle-treated rats (19.9±2.0 mg/mm vs 30.4± 2.4 mg/mm, p<0.05, Table 11 ). Thus, resveratrol also attenuated myocarditis when it was given after immunization.
Discussion
In this study, resveratrol preserved the cardiac function protein was increased in the hearts of myosin-immunized rats. Vehicletreated unimmunized rats (n=4), resveratrol-treated unimmunized rats (n=4), vehicle-treated myosin-immunized rats (n=5), and resveratroltreated myosin-immunized rats (n=5) were used for the analysis. *p<0.05 vs unimmunized rats treated with vehicle, † p<0.05 vs vehicletreated myosin-immunized rats. The mean value of vehicle-treated unimmunized rat was defined as 1 unit. GAPDH, glyceraldehye-3-phosphate dehydrogene. of EAM rats. It attenuated the increase in heart weight and suppressed the expression of pro-inflammatory genes. The attenuation of myocardial injury was associated with a decrease in antioxidant gene expressions. SIRT1, a possible effector of resveratrol, was increased in the myocardium of EAM rats, and was mainly localized in infiltrating mononuclear cells.
In this study, we used DMSO as the solvent, because we needed to administer a relatively high dose of resveratrol, and it is known to have an immunomodulatory function. 24, 25 We administered 0.5 ml of DMSO or the same amount of saline to myosin-immunized rats for 14 days. The heart weight/tibial length ratio of DMSO-treated myosin-immunized rats was reduced compared with saline-treated myosin-immunized rats (31.9±2.6 mg/mm vs 41.8±1.6 mg/mm, p<0.05), although the effect of DMSO was much weaker than resveratrol dissolved in DMSO. Thus, it is possible that the strong suppression of the inflammatory response was a synergistic effect of DMSO and resveratrol.
The HR of myosin-immunized rats was higher than that of unimmunized rats on BP measurement without anesthesia, whereas that of myosin-immunized rats was lower than in unimmunized rats on echocardiographic analysis with anesthesia. It is likely that the response of myosin-immunized rats to anesthesia was different from that of unimmunized rats.
The mechanism of resveratrol's attenuation of EAM is unknown. Resveratrol is reported to reduce oxidative stress 26, 27 and in this study, the expression of oxidative stress-related genes (Mn-SOD, Cu/Zn-SOD) were increased in the heart of myosin-immunized rats. This increase of both was likely the result of increased oxidative stress, and attenuation of myocarditis was associated with a decrease of Mn-SOD and Cu/Zn-SOD. Thus, resveratrol may ameliorate EAM by reducing oxidative stress because oxygen radical scavengers are known to attenuate myocarditis. 28, 29 Alternatively, resveratrol may modulate EAM by acting on SIRT1, which was increased in the myocardium of myosin-immunized rats, and mainly localized in the infiltrating mononuclear cells. Fibroblasts deficient in SIRT1 proliferate more rapidly than wild-type cells. 30 SIRT1 induces cellcycle arrest by activating the Forkhead transcription factor. 31 Resveratrol also inhibits the proliferation of some tumors. 9, 10 Thus, it is possible that resveratrol modulates the activity of SIRT1 in immune cells, and limits lymphocyte proliferation. However, the role of SIRT1 in immune cells is currently unknown and further studies are needed to clarify its role in EAM.
We used a relatively high dose of resveratrol. The HW/TL ratio of myosin-immunized rats treated with a lower dose of resveratrol (10 mg/kg per day) was not different from that of vehicle-treated myosin-immunized rats (43.9±6.7 mg/mm vs 43.3±3.9 mg/mm). Resveratrol is reported to have different effects on immune cells, depending on the dose and experimental condition. 32, 33 In conclusion, resveratrol effectively ameliorated EAM. Although further study is needed, resveratrol may be a therapeutic modality for myocarditis.
